Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925519 | 1.00 | HPGD (0.31) | HPGDL3MBTL1CYP2D6KMT2ATSHR | |
| SCHEMBL2925521 | 1.00 | HPGD (0.31) | HPGDL3MBTL1CYP2D6KMT2ATSHR | |
| SCHEMBL1270368 | 0.75 | — | — | |
| SCHEMBL1270366 | 0.75 | — | — | |
| SCHEMBL1270364 | 0.75 | — | — | |
| SCHEMBL5911989 | 0.75 | HPGD (0.32) | HPGDL3MBTL1CYP2D6KMT2AUSP2 | |
| SCHEMBL5911994 | 0.75 | HPGD (0.32) | HPGDL3MBTL1CYP2D6KMT2AUSP2 | |
| SCHEMBL5911984 | 0.75 | HPGD (0.32) | HPGDL3MBTL1CYP2D6KMT2AUSP2 | |
| SCHEMBL5153228 | 0.75 | HPGD (0.33) | HPGDL3MBTL1CYP2D6KMT2ATSHR | |
| SCHEMBL7614503 | 0.75 | HPGD (0.33) | HPGDL3MBTL1CYP2D6KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838653-B1 | NOVEL TRIMETHYLCYCLODODECATRIENE DERIVATIVES, USE THEREOF, AND PERFUMED PRODUCTS CONTAINING THE SAME | MANE FILS V (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-7737107-B2 | Trimethylcyclododecatriene derivatives, use thereof and perfumed products containing the same | Fils, V. Mane (FR) | 2010-06-15 | — | — | US | disclosed |
| US-20080139446-A1 | Novel Trimethylcyclodoecatriene Derivatives, Use Thereof And Perfumed Products Containing The Same | V. MANE FILS (FR) | 2008-06-12 | — | — | US | disclosed |
| EP-1838653-A1 | NOVEL TRIMETHYLCYCLODODECATRIENE DERIVATIVES, USE THEREOF, AND PERFUMED PRODUCTS CONTAINING THE SAME | V. Mane Fils (FR) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006077306-A1 | NOVEL TRIMETHYLCYCLODODECATRIENE DERIVATIVES, USE THEREOF, AND PERFUMED PRODUCTS CONTAINING THE SAME | V. MANE FILS (FR) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139446-A1 | Novel Trimethylcyclodoecatriene Derivatives, Use Thereof And Perfumed Products Containing The Same | CBR3, C5, OXER1 | HPGD 1225/4885L3MBTL1 1280/4885CYP2D6 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.